Monopar Therapeutics
MNPR
18 hedge funds and large institutions have $57.1M invested in Monopar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
53,861% more capital invested
Capital invested by funds: $106K → $57.1M (+$57M)
200% more funds holding
Funds holding: 6 → 18 (+12)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
41.96% more ownership
Funds ownership: 0.45% → 42.41% (+42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$17.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.58M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.82M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$4.2K |
MNPR Hedge Fund Activity: Q4 2024 in Review
18 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2024, worth a combined $57.1M — up 53,861% from $106K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MNPR positions and 0 closed out — a net gain of 12 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $17.6M. The largest seller was Wells Fargo, cutting an estimated $4.2K.
- 18 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $57.1M of Monopar Therapeutics stock for Q4 2024, up 53,861% quarter-over-quarter.
- 12 funds opened new Monopar Therapeutics positions in Q4 2024 and 0 closed out, a net change of +12 holders.
- The largest Monopar Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $17.6M added.
- The largest Monopar Therapeutics seller in Q4 2024 was Wells Fargo, an estimated $4.2K sold.
Based on aggregated 13F filings for Q4 2024.